Advocacy intelligence hub — real-time data for patient organizations
M.D. Anderson Cancer Center — PHASE1, PHASE2
Jonsson Comprehensive Cancer Center — PHASE1, PHASE2
Anhui Provincial Hospital — NA
Zhu Xiaofan — NA
University Health Network, Toronto — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Rituxan SC
Genentech, Inc.
Fludara
Berlex Laboratories, Inc.
Patient Assistance Programs3
BRUKINSA
(zanubrutinib)Orphan drugBeOne Medicines USA, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cyste...
Rituxan SC
(rituximab and recombinant human hyaluronidase)Orphan drugGenentech, Inc.
Bendeka
(bendamustine for 50 ml admixture)Orphan drugEagle Pharmaceuticals, Inc.
12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and it...
ARZERRA
(ofatumumab)Orphan drugNovartis Pharmaceuticals Corporation
CD20-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expr...
Treanda
(Bendamustine hydrochloride)Orphan drugCephalon, Inc.
12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and it...
Campath
(alemtuzumab)Orphan drugGenzyme Corporation
CD52-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action CAMPATH binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cel...
Fludara
(Fludarabine phosphate)Orphan drugBerlex Laboratories, Inc.
12.1 Mechanism of Action Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine ...
Zydelig
(idelalisib)Orphan drugstandardGilead Sciences, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ, which is expressed in normal and malignant B-cells. Idela...
A case of T-prolymphocytic leukemia harboring RAS mutation.
The text reports the clinical case of a 61-year-old woman with a long history of generalized pruritus who was eventually diagnosed with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive T-...
Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive malignancy with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HCT) is often used for treatment, but its effectiv...
How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas.
T-cell non-Hodgkin lymphomas, which arise from post-thymic mature T cells, constitute approximately 10-15% of all non-Hodgkin lymphomas. Their leukemic presentations, referred to here as mature T-cell...
Cutaneous-Only Relapse in T-Cell Prolymphocytic Leukemia With JAK2 Rearrangement.
Cutaneous-Only Relapse in T-Cell Prolymphocytic Leukemia With JAK2 Rearrangement.
Splenic B-Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement.
Splenic B-cell lymphoma/leukemia includes a group of indolent small B-cell lymphomas/leukemias that share overlapping morphological and immunophenotypic features, making accurate diagnosis challenging...
A Rare Presentation of T-cell Prolymphocytic Leukemia With Abnormal Uterine Bleeding.
T-cell prolymphocytic leukemia (T-PLL) is a rare and clinically aggressive T-cell neoplasm, which is composed of lymphoid cells that are of post-thymic T-cell origin. This is a case of a 57-year-old f...
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Heng Mei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tapan M Kadia
M D Anderson Cancer Center
📍 Houston, Texas
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Thomas C. Shea, MD
UNC Lineberger Comprehensive Cancer Center
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center